Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

New recommendations for the quality and safety of tissues and cells for clinical application and its significance for the practice of tissue establishments performing cryopreservation

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F21%3A10438980" target="_blank" >RIV/00179906:_____/21:10438980 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216208:11150/21:10438980

  • Výsledek na webu

    <a href="https://doi.org/10.18462/iir.cryo.2021.0038" target="_blank" >https://doi.org/10.18462/iir.cryo.2021.0038</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.18462/iir.cryo.2021.0038" target="_blank" >10.18462/iir.cryo.2021.0038</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    New recommendations for the quality and safety of tissues and cells for clinical application and its significance for the practice of tissue establishments performing cryopreservation

  • Popis výsledku v původním jazyce

    The processes of procurement, processing, storage and distribution of cells and tissues of human origin used for clinical application are regulated in the European Union member states by the Directive of the European Parliament and Council No.2004/23/EC harmonized in the Czech Republic by the Act No.296/2008 Coll. and the Decree of the Ministry of Health No. 422/2008 Coll. In the Evaluation report from 2019 dealing with fulfilling of requirements of the above mentioned Directive in individual member states, the European Commission pointed out the significance of the document: &quot;Guide to the Quality and Safety of Tissues and Cells for Human Application&quot;, the 4th Edition, issued by the European Directorate for the Quality of Medicines in 2019. This document includes specifications of cryopreserved haematopoietic progenitor cells derived from bone marrow, peripheral blood and cord blood as well as of non-mobilized peripheral blood mononuclear cells. The cryoprotectant dimethylsulphoxide (DMSO) is recommended to be used in concentrations 5 - 10 % (v/v) and in the daily dose not exceeding 1 g per kg of the patient&apos;s weight. DMSO removal before clinical administration is recommended to be performed in specific situations defined in the standard operating procedures of the tissue establishment. A guide defining Good Tissue Practice is a part of this document. The authors expect that the above cited document represents a basis for the planed upgrade of the Directive 2004/23/EC and of the Commission Directives 2006/17/EC and 2006/86/EC.

  • Název v anglickém jazyce

    New recommendations for the quality and safety of tissues and cells for clinical application and its significance for the practice of tissue establishments performing cryopreservation

  • Popis výsledku anglicky

    The processes of procurement, processing, storage and distribution of cells and tissues of human origin used for clinical application are regulated in the European Union member states by the Directive of the European Parliament and Council No.2004/23/EC harmonized in the Czech Republic by the Act No.296/2008 Coll. and the Decree of the Ministry of Health No. 422/2008 Coll. In the Evaluation report from 2019 dealing with fulfilling of requirements of the above mentioned Directive in individual member states, the European Commission pointed out the significance of the document: &quot;Guide to the Quality and Safety of Tissues and Cells for Human Application&quot;, the 4th Edition, issued by the European Directorate for the Quality of Medicines in 2019. This document includes specifications of cryopreserved haematopoietic progenitor cells derived from bone marrow, peripheral blood and cord blood as well as of non-mobilized peripheral blood mononuclear cells. The cryoprotectant dimethylsulphoxide (DMSO) is recommended to be used in concentrations 5 - 10 % (v/v) and in the daily dose not exceeding 1 g per kg of the patient&apos;s weight. DMSO removal before clinical administration is recommended to be performed in specific situations defined in the standard operating procedures of the tissue establishment. A guide defining Good Tissue Practice is a part of this document. The authors expect that the above cited document represents a basis for the planed upgrade of the Directive 2004/23/EC and of the Commission Directives 2006/17/EC and 2006/86/EC.

Klasifikace

  • Druh

    D - Stať ve sborníku

  • CEP obor

  • OECD FORD obor

    30205 - Hematology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2021

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název statě ve sborníku

    Cryogenics 2021 online. The 16th Cryogenics 2021 IIR International Conference, October 5-7, 2021. Proceedings

  • ISBN

    978-2-36215-047-0

  • ISSN

    0151-1637

  • e-ISSN

  • Počet stran výsledku

    6

  • Strana od-do

    167-172

  • Název nakladatele

    International Institute of Refrigeration

  • Místo vydání

    Paris

  • Místo konání akce

    Czech Republic

  • Datum konání akce

    5. 10. 2021

  • Typ akce podle státní příslušnosti

    WRD - Celosvětová akce

  • Kód UT WoS článku

    001304907400021